90 related articles for article (PubMed ID: 10483869)
41. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists.
Fromm G; de Silva S; Schreiber TH
Front Immunol; 2023; 14():1236332. PubMed ID: 37795079
[TBL] [Abstract][Full Text] [Related]
42. Lymphocytic tumor necrosis factor receptor superfamily co-stimulatory molecules in the pathogenesis of atherosclerosis.
Smeets E; Meiler S; Lutgens E
Curr Opin Lipidol; 2013 Dec; 24(6):518-24. PubMed ID: 24184937
[TBL] [Abstract][Full Text] [Related]
43. CD30 plays a role in T-dependent immune response and TÂ cell proliferation.
Cui D; Zhang Y; Chen L; Du H; Zheng B; Huang M; Li X; Wei J; Chen Q
FASEB J; 2024 Jan; 38(1):e23365. PubMed ID: 38069862
[TBL] [Abstract][Full Text] [Related]
44. Signaling by the TNF receptor superfamily and T cell homeostasis.
Chan KF; Siegel MR; Lenardo JM
Immunity; 2000 Oct; 13(4):419-22. PubMed ID: 11070160
[No Abstract] [Full Text] [Related]
45. Pathways leading to cell death in T cells.
Wong B; Choi Y
Curr Opin Immunol; 1997 Jun; 9(3):358-64. PubMed ID: 9203409
[TBL] [Abstract][Full Text] [Related]
46. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management.
Fleming D; Stone J; Tansley P
Aesthetic Plast Surg; 2018 Jun; 42(3):672-678. PubMed ID: 29445921
[TBL] [Abstract][Full Text] [Related]
47. Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).
Burgess SC; Young JR; Baaten BJ; Hunt L; Ross LN; Parcells MS; Kumar PM; Tregaskes CA; Lee LF; Davison TF
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13879-84. PubMed ID: 15356338
[TBL] [Abstract][Full Text] [Related]
48. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.
Fujii H; Hasegawa M; Takehara K; Mukaida N; Sato S
Clin Exp Immunol; 2002 Dec; 130(3):548-56. PubMed ID: 12452848
[TBL] [Abstract][Full Text] [Related]
49. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft M
Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
[TBL] [Abstract][Full Text] [Related]
50. Expression and function of CD30 on T lymphocytes.
Tarkowski M
Arch Immunol Ther Exp (Warsz); 1999; 47(4):217-21. PubMed ID: 10483869
[TBL] [Abstract][Full Text] [Related]
51. Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms.
Toennies HM; Green JM; Arch RH
J Leukoc Biol; 2004 Feb; 75(2):350-7. PubMed ID: 14634058
[TBL] [Abstract][Full Text] [Related]
52. CD30: expression and function in health and disease.
Horie R; Watanabe T
Semin Immunol; 1998 Dec; 10(6):457-70. PubMed ID: 9826579
[TBL] [Abstract][Full Text] [Related]
53. Regulation of immune responses by the ligands for CD27, CD30, and 4-1BB.
Alderson MR
Circ Shock; 1994 Oct; 44(2):73-6. PubMed ID: 7743603
[TBL] [Abstract][Full Text] [Related]
54. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells.
D'Elios MM; Romagnani P; Scaletti C; Annunziato F; Manghetti M; Mavilia C; Parronchi P; Pupilli C; Pizzolo G; Maggi E; Del Prete GF; Romagnani S
J Leukoc Biol; 1997 May; 61(5):539-44. PubMed ID: 9129201
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
